MariMed Inc (MRMD)
OTHER OTC:MRMD
Want to see MRMD full AI Analyst Report?
MRMD Stock Chart & Stats
$0.07
<$0.01(0.85%)
At close: 4:00 PM EST
$0.07
<$0.01(0.85%)
Day’s Range― - ―
52-Week Range$0.06 - $0.23
Previous CloseN/A
Volume101.75K
Average Volume (3M)1.40M
Market Cap
$29.94M
Enterprise Value$120.15M
Total Cash (Recent Filing)$7.94M
Total Debt (Recent Filing)$98.14M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 12, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding399,266,080
10 Day Avg. Volume1,629,378
30 Day Avg. Volume1,398,937
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.66
Price to Sales (P/S)0.21
P/FCF Ratio5.25
Enterprise Value/Market Cap4.01
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit2.07
Enterprise Value/Ebitda11.16
Forecast
1Y Price Target
$0.25Price Target Upside257.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$161.35M
Bulls Say, Bears Say
Bulls Say
Positive Operating And Free Cash FlowConsistent positive operating and free cash flow (TTM ~$7.4M and ~$5.8M) provides a durable internal funding source to support capex, licensing and modest expansion. Over 2–6 months this reduces reliance on immediate external financing and helps bridge losses, though scale limits remain.
Wholesale Growth In Key StatesStrong wholesale momentum in Delaware and Illinois broadens distribution and reduces single-channel reliance. Durable wholesale expansion can drive steadier revenue streams, scale manufacturing economics, and improve negotiating power with retailers over the medium term.
Large Loyalty Base And Digital AdoptionA large, growing loyalty base and over 50% digital/advance orders imply recurring revenue, stronger retention and lower customer acquisition costs. Structural digital adoption supports healthier margins and merchandising leverage across channels over the next several quarters.
Bears Say
Very High LeverageExtremely high leverage (debt-to-equity ~13x) materially constrains strategic flexibility, raises refinancing risk and limits capacity to invest or absorb shocks. Even with positive cash flow, interest and principal burdens increase the chance of funding stress over the medium term.
Compressed Margins And Ongoing GAAP LossesSustained margin compression and continued GAAP net losses reduce the company's ability to self-fund growth or rebuild equity. Lower gross margins and only modest EBITDA margins limit reinvestment capacity and increase sensitivity to price competition and cost shocks over months.
Financing Restructure Raises Dilution And ComplexityRestructuring removed near-term cash pressure but created senior preferred securities and convertible claims that can dilute common equity and complicate the capital structure. Over time this can restrict strategic options, deter new equity holders and raise long-term shareholder dilution risk.
MariMed News
MRMD FAQ
What was MariMed Inc’s price range in the past 12 months?
MariMed Inc lowest stock price was $0.06 and its highest was $0.23 in the past 12 months.
What is MariMed Inc’s market cap?
MariMed Inc’s market cap is $29.94M.
When is MariMed Inc’s upcoming earnings report date?
MariMed Inc’s upcoming earnings report date is Aug 12, 2026 which is in 79 days.
How were MariMed Inc’s earnings last quarter?
MariMed Inc released its earnings results on May 13, 2026. The company reported -$0.008 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.002.
Is MariMed Inc overvalued?
According to Wall Street analysts MariMed Inc’s price is currently Undervalued.
Does MariMed Inc pay dividends?
MariMed Inc does not currently pay dividends.
What is MariMed Inc’s EPS estimate?
MariMed Inc’s EPS estimate is -0.01.
How many shares outstanding does MariMed Inc have?
MariMed Inc has 399,266,080 shares outstanding.
What happened to MariMed Inc’s price movement after its last earnings report?
MariMed Inc reported an EPS of -$0.008 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of MariMed Inc?
Currently, no hedge funds are holding shares in MRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MariMed Inc
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
MRMD Company Deck
MRMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic tone: the company delivered year-over-year revenue growth, positive adjusted EBITDA, stable gross margins above 40%, strong wholesale momentum in Delaware and Illinois, and robust loyalty/digital adoption—offset by expected seasonal retail softness, sequential declines in revenue and EBITDA, ongoing price compression in several markets, a continued GAAP net loss and a modest decline in cash. Management emphasized brand strength, operational discipline, and opportunities from medical rescheduling and state-level expansion (Massachusetts cap increase, Ohio store opening, licensing activity in NY/PA/Maine) while acknowledging near-term headwinds.View all MRMD earnings summariesMRMD Stock 12 Month Forecast
Average Price Target
$0.25
▲(257.14% Upside)
Technical Analysis
Ownership Overview
10.68% Insiders
0.18% Other Institutional Investors
89.14% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---